Is COVID vaccine effective in patients with myeloid malignancy?
作者信息
Mittelman Moshe
机构信息
Department of Hematology, Tel Aviv Sourasky (Ichilov) Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
出版信息
Br J Haematol. 2022 Jun;197(6):656-658. doi: 10.1111/bjh.18155. Epub 2022 Apr 5.
Abstract
摘要
相似文献
1
Is COVID vaccine effective in patients with myeloid malignancy?
Br J Haematol. 2022 Jun;197(6):656-658. doi: 10.1111/bjh.18155. Epub 2022 Apr 5.
2
Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.
Br J Haematol. 2022 Jun;197(6):691-696. doi: 10.1111/bjh.18138. Epub 2022 Mar 14.
3
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms.
Leukemia. 2021 Dec;35(12):3573-3577. doi: 10.1038/s41375-021-01300-7. Epub 2021 May 22.
4
Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines.
Leukemia. 2021 Dec;35(12):3578-3580. doi: 10.1038/s41375-021-01457-1. Epub 2021 Nov 5.
5
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.
J Hematol Oncol. 2021 May 17;14(1):81. doi: 10.1186/s13045-021-01090-6.
6
Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience.
Blood Cancer J. 2021 Nov 26;11(11):185. doi: 10.1038/s41408-021-00579-0.
7
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
8
SARS-CoV-2 vaccine candidates in rapid development.
Hum Vaccin Immunother. 2021 Mar 4;17(3):644-653. doi: 10.1080/21645515.2020.1804777. Epub 2020 Oct 29.
9
Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection.
Infection. 2022 Jun;50(3):791-793. doi: 10.1007/s15010-021-01729-z. Epub 2021 Dec 2.
10
[SARS-CoV-2 vaccines].
Ugeskr Laeger. 2021 Mar 8;183(10).
引用本文的文献
1
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario.
Cancers (Basel). 2022 Nov 9;14(22):5512. doi: 10.3390/cancers14225512.
2
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report.
Hemasphere. 2022 Oct 25;6(11):e789. doi: 10.1097/HS9.0000000000000789. eCollection 2022 Nov.
本文引用的文献
1
Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.
Br J Haematol. 2022 Jun;197(6):691-696. doi: 10.1111/bjh.18138. Epub 2022 Mar 14.
2
Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies.
Hemasphere. 2022 Feb 15;6(3):e686. doi: 10.1097/HS9.0000000000000686. eCollection 2022 Mar.
3
COVID-specific T's may offset therapeutically endangered B's.
Blood. 2022 Jan 6;139(1):12-13. doi: 10.1182/blood.2021014466.
4
Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients.
Blood. 2022 Jan 6;139(1):142-147. doi: 10.1182/blood.2021013445.
5
Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting.
Blood. 2022 Mar 10;139(10):1439-1451. doi: 10.1182/blood.2021013768.
6
Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma.
Blood. 2022 Jan 6;139(1):137-142. doi: 10.1182/blood.2021013429.
7
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study.
Lancet Rheumatol. 2021 Nov;3(11):e789-e797. doi: 10.1016/S2665-9913(21)00251-4. Epub 2021 Sep 7.
8
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.
Blood Adv. 2021 Aug 24;5(16):3053-3061. doi: 10.1182/bloodadvances.2021005094.
9
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.
Cancer Cell. 2021 Aug 9;39(8):1034-1036. doi: 10.1016/j.ccell.2021.07.016. Epub 2021 Jul 27.
10
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.
Haematologica. 2022 Mar 1;107(3):715-720. doi: 10.3324/haematol.2021.279216.
Zotero 插件